Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
09/2005
09/28/2005EP1000085B1 Treatment of insulin resistance with growth hormone secretagogues
09/28/2005EP0991763B1 Modified adenoviral fiber and target adenoviruses
09/28/2005EP0977871B1 Neurotrypsin
09/28/2005EP0944639A4 Synthetic glycoamines, methods for their use that affect cell
09/28/2005EP0767835B1 Denervated muscle kinase (dmk), a receptor of the tyrosine kinase super family
09/28/2005EP0743955B1 Cyclic nerve growth factor (ngf) structural analogs and their uses
09/28/2005EP0646022B1 Prosthetic devices having enhanced osteogenic properties
09/28/2005EP0552202B2 Methods mediated by the proto-oncogenic protein complex AP-1
09/28/2005CN1675374A Treatment of liver diseases
09/28/2005CN1675363A T-cell epitopes in staphylococcal enterotoxin B
09/28/2005CN1675362A HLA-A24-restricted cancer antigen peptide
09/28/2005CN1675359A Novel forms of interfering rna molecules
09/28/2005CN1675353A Substances for preventing and treating autoimmune diseases
09/28/2005CN1675242A T-cell epitopes in erythropoietin
09/28/2005CN1675241A Immunogenic conjugates
09/28/2005CN1675237A Immunogenic compositions
09/28/2005CN1675236A Antibacterial amide macrocycles
09/28/2005CN1675165A Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
09/28/2005CN1674942A Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation
09/28/2005CN1674931A T cell receptor CDR3 sequences and methods for detection
09/28/2005CN1674930A Enzyme containing composition, process of producing said composition and its use
09/28/2005CN1674929A Use of protein kinase N beta
09/28/2005CN1674928A Method for treatment of indwelling catheter occlusion using fibrinolytic metalloproteinases
09/28/2005CN1674927A Growth hormone releasing peptides
09/28/2005CN1674923A Non-polymeric hematopoeitic cell clots for delivery of active agents
09/28/2005CN1674919A Use of cgrp antagonist compounds for treatment of psoriasis
09/28/2005CN1674869A Cochleates without metal cations as the bridging agents
09/28/2005CN1674795A Method and composition for treating or preventing catabolism or stimulating anabolism in a mammal undergoing metabolic stress
09/28/2005CN1673744A Treatment and diagnosis of cancer
09/28/2005CN1673372A A novel marnifi blue mold cell wall surface antigen II its coding sequence and application thereof
09/28/2005CN1673371A A new marnifi blue mold cell wall surface antigen I, its coding sequence and application thereof
09/28/2005CN1673363A Pallas pit viper active hepatoenzyme
09/28/2005CN1673361A Multipotential cell containing heterogenous nuclear and mitochondrion
09/28/2005CN1673230A Prepn of recombinant composite interferon-polyglycol conjugate and conjugate product
09/28/2005CN1672732A Stable recombinant solid alpha-interferon composition
09/28/2005CN1672731A Interferon spray for lung administration and its prepn process
09/28/2005CN1220705C Alpha-lipoic acid and its derivative modified insulin and preparing method thereof
09/28/2005CN1220704C Cholalic acid derivative medified insulin and preparing method thereof
09/28/2005CN1220702C Insulinotropic peptide and its use
09/28/2005CN1220701C Recombinded chemotaxis cytokine of human cirumferential lymphatic tissue as well as its preparing method and use
09/28/2005CN1220700C Staphylococcus aureus virulence stimulating factor inhibiting peptide and its application
09/28/2005CN1220683C Acyl derivatives for treating VLA-4 related disorders
09/28/2005CN1220520C Inhibition of 2, 3-dihydrogen-indone to 26S and 20S prolease
09/28/2005CN1220484C Microparticles for pulmonary administation
09/27/2005US6949681 Intermediate for preparing glycopeptide derivatives
09/27/2005US6949636 Intron/exon structure of the human and mouse β3-adrenergic receptor genes
09/27/2005US6949625 Injectable implant of insoluble globin
09/27/2005US6949624 mediates the assembly of transcription repressor complexes by altering chromatin structure
09/27/2005US6949570 Carboxyalkyl substituted sulfonamidomethyl amides or ureas used for treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, and diabetes
09/27/2005US6949547 Antidiabetic agents; central nervous system disorders; cardiovascular disorders; hypotensive agents; anticancer agents
09/27/2005US6949530 Hypotensive agents
09/27/2005US6949520 Methods related to immunostimulatory nucleic acid-induced interferon
09/27/2005US6949516 Oligopeptides used as antiapoptosis agents
09/27/2005US6949515 Amino acid side chain-modified substrates of the enzyme; obtaining locally limited inhibition; treating inflammation, psoriasis, periodontitis, allergies, arthritis, tumors or autoimmune diseases
09/27/2005US6949514 Administering to a subject in need of such treatment, an agent in an amount effective to inhibit proliferation
09/27/2005US6949513 For therapy of oral, pancreatic, colon, lung, breast or leukemia cancers
09/27/2005US6949512 administering to patient effective amount of lipopolysaccharide binding protein to elevate serum concentration of lipopolysaccharide binding protein in patient to sufficiently high level to suppress lipopolysaccharide induced release of cytokine
09/27/2005US6949511 Methods of inhibiting angiogenesis via increasing in vivo concentrations of kringle region fragments of plasminogen
09/27/2005US6949509 Pharmaceutical composition containing a small or medium size peptide
09/27/2005US6949507 Use of agents which bind G proteins for treating septic shock
09/27/2005US6949506 Relaxin-like factor and methods and uses thereof
09/27/2005US6949505 contacting neuron with a morphogen containing a dimeric protein having specific amino acid sequence :
09/27/2005US6949366 Complexing; purified polypeptide
09/27/2005US6949365 Gonadotropin-releasing hormone (GnRH-III); for controlling the gonadal development and spawning, maturation, and reproduction of fish
09/27/2005US6949363 An antisense compound 8 to 30 nucleotides in length that specifically hybridizes to a nucleic acid molecule(cDNA) encoding the human leucin-rich repeat bone marrow protein or polypeptide to prevent the expression of such protein
09/27/2005US6949360 DNA coding for human cell surface antigen
09/27/2005US6949359 Human IL-1 epsilon DNA and polypeptides
09/27/2005US6949358 Human tumor necrosis factor receptor TR9
09/27/2005US6949356 Methods for improving secondary metabolite production in fungi
09/27/2005US6949352 Serine-threonine phosphatase protein of a parasitic organism of the Apicomplexa phylum, applications in therapeutics
09/27/2005US6949349 incubating a phagemid clone displaying the peptide, with the IGF in the presence of the IGFBP at high and low concentrations of the phagemid clone, measuring the degree to which binding of the phagemid clone to the IGFBP is inhibited by IGF
09/27/2005US6949341 Diagnosing genetic disorders
09/27/2005US6949337 Contacting human vpr interacting protein with a test compound and comparing the affinity of the vpr in the presence and absence of it
09/27/2005US6949258 The invention is directed to an oral biological preparation for specific delivery in colon, especially an oral insulin preparation for specific delivery in colon.
09/27/2005US6949246 Monoclonal/polyclonal antibodies for serodetection and treatment of mycobacterium infections
09/27/2005US6949244 produced by hybridoma cell line ATCC No. HB 12020; elicits an immune response against (human milk fat globule) HMFG in non-human primates
09/27/2005CA2255539C Therapeutic uses of bpi protein products in humans with hemorrhage due to trauma
09/27/2005CA2250682C Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
09/27/2005CA2149120C Monoclonal antibody which specifically binds to tumor vascular endothelium and uses thereof
09/27/2005CA2108104C Fibrin sealant compositions and methods for utilizing same
09/27/2005CA2099612C Monokine mig induced by ifn-gamma
09/26/2005WO2005110452A2 MULTIPLE-VARIABLE DOSE REGIMEN FOR TREATING TNFα-RELATED DISORDERS
09/26/2005CA2847331A1 Multiple-variable dose regimen for treating tnf.alpha.-related disorders
09/26/2005CA2847142A1 Multiple-variable dose regimen for treating tnf.alpha.-related disorders
09/26/2005CA2504868A1 Multiple-variable dose regimen for treating tnf.alpha. related disorders
09/22/2005WO2005087954A2 Roles of foxc2, pdgfr, vegfr3 in lymphatic vessel development
09/22/2005WO2005087926A2 Multiple promoter expression cassettes for simultaneous delivery of rnai agents
09/22/2005WO2005087925A1 Recombinant gene, disease animal model and method of evaluating test substance
09/22/2005WO2005087920A2 Recombinant chondroitinase abc i and uses thereof
09/22/2005WO2005087806A2 Cd38 splice variant and uses thereof
09/22/2005WO2005087805A1 Treating or preventing extracellular matrix build-up
09/22/2005WO2005087804A1 Erythropoietin liquid formulation
09/22/2005WO2005087801A1 Peptide carrier for drug delivery
09/22/2005WO2005087798A1 D-ser!8-cyclosporine modified on the hydroxyl group having a switchable inhibiting effect on protein phosphatase calcineurine and specific manipulipulatability obtained therewith of the immunosuppressive effect while maintaining inhibition of peptidyl-prolyl-cis-trans-isomerase (ppi) e.g. for the treatment of autoimmune d
09/22/2005WO2005087797A1 Methods and compositions for the treatment of gastrointestinal disorders
09/22/2005WO2005087796A1 Novel phosphorylated sequences of phosphatase cdc25b, antibodies directed against said sequences and use thereof
09/22/2005WO2005087795A1 Use of peptides as penetrating cell carriers
09/22/2005WO2005087794A1 Process for octreotide synthesis
09/22/2005WO2005087730A1 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis c virus ns3 serine protease
09/22/2005WO2005087725A2 Novel compounds as inhibitors of hepatitis c virus ns3 serine protease
1 ... 1373 1374 1375 1376 1377 1378 1379 1380 1381 1382 1383 1384 1385 1386 1387 1388 1389 1390 1391 1392 1393 ... 3163